Emcure Pharmaceuticals

1,029.70
-43.50
(-4.05%)
Market Cap
19,505.80 Cr
EPS
27.54
PE Ratio
33.54
Dividend Yield
0.18 %
Industry
Healthcare
52 Week High
1,580.00
52 Week Low
889.00
PB Ratio
4.95
Debt to Equity
0.86
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+66.67 %
+66.67 %
Hold
Hold+33.33 %
+33.33 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Emcure Pharma Receives EIR from USFDA for API Facility6 days ago
Emcure Pharmaceuticals has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility located in Kurkumbh, Pune. The facility has been classified as 'Voluntary Action Indicated' (VAI), which suggests that while some objectionable conditions were found, they do not warrant further regulatory action.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,787.40
#1 4,28,857.13
36.71
#1 49,887.20
12.06
#1 9,648
13.77
59.27
6,012.50
1,59,612.98
79.83
8,184.00
0.89
1,600
#1 64.53
57.99
1,525.90
1,23,233.96
25.11
26,520.70
14.17
4,155
47.38
57.43
3,238.90
1,09,619.09
60.42
10,785.70
11.59
1,656
13.54
52.37
2,557.50
1,05,516.96
52.60
10,615.60
19.57
1,942
-16.38
59.98
1,174.80
98,031.82
#1 18.66
28,905.40
12.36
5,578
1.69
54.12
2,019.60
92,203.01
33.50
20,141.50
#1 19.94
1,936
38.82
50.28
859.65
86,500.90
19.53
19,831.50
13.82
3,831
29.92
46.44
1,220.10
70,863.61
20.72
29,559.20
17.55
3,169
-10.04
58.85
29,705.00
63,121.05
47.82
6,097.20
10.80
1,201
16.01
45.94
Growth Rate
Revenue Growth
11.33 %
Net Income Growth
-6.09 %
Cash Flow Change
46.92 %
ROE
-20.28 %
ROCE
-20.23 %
EBITDA Margin (Avg.)
-5.80 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,571
1,664
1,697
1,783
1,839
2,038
1,959
Expenses
1,261
1,337
1,381
1,460
1,479
1,621
1,601
EBITDA
311
327
316
323
360
417
359
Operating Profit %
19 %
20 %
17 %
18 %
19 %
19 %
18 %
Depreciation
67
70
84
91
94
97
97
Interest
52
59
61
66
59
46
32
Profit Before Tax
191
198
171
167
207
273
230
Tax
50
52
51
46
55
72
74
Net Profit
141
146
120
121
153
202
156
EPS in ₹
7.21
7.70
6.27
6.36
7.95
10.23
8.12

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
Total Assets
5,247
5,644
6,004
6,807
6,064
6,673
7,806
Fixed Assets
2,049
2,247
2,382
2,188
2,044
2,147
3,125
Current Assets
2,335
2,453
2,703
3,718
3,424
3,836
4,260
Capital Work in Progress
531
581
485
302
320
411
159
Investments
0
0
0
0
25
25
318
Other Assets
2,667
2,817
3,137
4,318
3,674
4,089
4,204
Total Liabilities
5,247
5,644
6,004
6,807
6,064
6,673
7,806
Current Liabilities
2,336
2,543
2,920
3,408
2,965
3,019
3,211
Non Current Liabilities
1,157
1,201
1,100
1,031
985
1,004
1,474
Total Equity
1,755
1,900
1,984
2,368
2,114
2,650
3,122
Reserve & Surplus
1,520
1,654
1,731
2,092
1,807
2,320
2,771
Share Capital
181
181
181
181
181
181
181

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
-700
32
259
42
134
219
Investing Activities
-409
-168
-257
-575
-468
-715
Operating Activities
444
500
704
768
747
1,097
Financing Activities
-735
-301
-189
-152
-145
-164

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
78.08 %
78.08 %
77.94 %
77.92 %
FIIs
1.76 %
2.91 %
3.05 %
3.07 %
DIIs
3.34 %
3.96 %
3.87 %
3.44 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.73 %
5.00 %
5.14 %
5.51 %
Others
9.10 %
10.04 %
10.00 %
10.06 %
No of Share Holders
4,98,006
1,52,914
1,43,449
1,39,671

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.00

Corporate Action

Announcements

Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - Update On USFDA Inspection At API Manufacturing Facility Located At Kurkumbh Pune Maharashtra India8 days ago
Intimation Of Change In Email And Website Address Of Registrar And Share Transfer Agent Of The Company8 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 31, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At API Manufacturing Facility Located At KuFeb 26, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At API Manufacturing Facility Located At Kurkumbh Pune Maharashtra IndiaFeb 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 06, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Feb 06, 2025
Integrated Filing (Financial)Feb 06, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On February 06 2025Feb 06, 2025
Unaudited Financial Results (Consolidated And Standalone) For The Quarter And Nine Months Ended December 31 2024Feb 06, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 05, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31 2024Jan 24, 2025
Press Release Titled Emcure Pharmaceuticals Inaugurates World-Class R&D Centre In Gujarat.Jan 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Intimation Of Change In Name Of Registrar And Share Transfer Agent Of The CompanyJan 02, 2025
Closure of Trading WindowDec 18, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementNov 29, 2024
Announcement under Regulation 30 (LODR)-Resignation of DirectorNov 23, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 23, 2024
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 22, 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 22, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 13, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 08, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Statement Of Deviation(S) Or Variation(S) Of Funds Under Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, For The Quarter Ended September 30, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 07, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On November 07, 2024Nov 07, 2024
Results - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2024
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half-Year Ended September 30, 2024Oct 29, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 28, 2024
Certificate Under Regulation 74(5) OfThe SEBI (Depositories And Participants) Regulations, 2018, For The Quarter Ended September 30, 2024Oct 07, 2024
Announcement under Regulation 30 (LODR)-AcquisitionOct 03, 2024
Press ReleaseOct 03, 2024
Closure of Trading WindowSep 26, 2024
Announcement under Regulation 30 (LODR)-AcquisitionSep 13, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2024

Technical Indicators

RSI(14)
Neutral
50.55
ATR(14)
Volatile
54.68
STOCH(9,6)
Overbought
82.20
STOCH RSI(14)
Neutral
79.31
MACD(12,26)
Bullish
10.83
ADX(14)
Weak Trend
22.23
UO(9)
Bearish
51.26
ROC(12)
Uptrend And Accelerating
4.28
WillR(14)
Neutral
-43.94

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes in orals, injectables, and biotherapeutics, covering areas such as gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, blood-related, and oncology treatments. The company has a portfolio of differentiated products, including chiral molecules, complex APIs, biologics, and novel drug delivery systems. Emcure has commercialized six in-house manufactured biologics and holds patents for specific treatments. The company expanded through mergers, acquisitions, and establishment of new facilities over the years. In July 2024, Emcure launched an Initial Public Offer.
Listing Date
10 Jul, 2024(0 Years, 48 days)
Chairperson NameBerjis M Desai